Rapid communicationAntiviral activity of 2′,3′-dideoxy-β-L-5-fluorocytidine (β-L-FddC) and 2′,3′-dideoxy-β-L-cytidine (β-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro
References (22)
- et al.
Hepatocellular carcinoma and hepatitis B virus
Lancet
(1981) - et al.
An in vitro system for screening anti-hepatitis B virus drugs
Virology
(1989) - et al.
Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine
J Biol Chem
(1989) - et al.
Preparation of the geometric isomers of DDC, DDA, D4C, and D4T as potential anti-HIV agents
Bioorg Med Chem Lett
(1991) - et al.
Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication
J Biol Chem
(1992) - et al.
Biochemical pharmacology of (+)- and (−)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents
J Biol Chem
(1992) - et al.
Bull World Health Organ
(1988) - et al.
Hepatocellular carcinoma
Ann Intern Med
(1988) - et al.
Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis
Antimicrob Agents Chemother
(1991) - et al.
The limitation of polynucleotide phosphorylase polymerization in the presence of L-ribonucleoside 5'-diphosphates
Nucleic Acids Res, Spec Publ No. 1
(1975)
L-Thymidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth
J Med Chem
(1992)
Cited by (0)
Copyright © 1994 Published by Elsevier Inc.